FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899694001> ?p ?o ?g. }

• W2899694001 abstract "The objective of the study was to examine overall anemia management trends in non-dialysis patients with chronic kidney disease (CKD) from 2006 to 2015, and to evaluate the impact of Trial to Reduced Cardiovascular Events with Ananesp Therapy (TREAT)'s study results (October 2009) and the US Food and Drug Administration (FDA)'s (June 2011) safety warnings and guidelines on the use of ESA therapy in the current treatment of anemia.A retrospective cohort analysis of anemia management in CKD patients using Truven MarketScan Commercial and Medicare Supplemental databases was conducted. Monthly rates and types of anemia treatment for post-TREAT and post-FDA safety warning periods were compared to pre-TREAT period. Anemia management included ESA, intravenous iron, and blood transfusion. A time-series analysis using Autoregressive Integrated Moving Average (ARIMA) model and a Generalized Estimating Equation (GEE) model were used.Between 2006 and 2015, CKD patients were increasingly less likely to be treated with ESAs, more likely to receive intravenous iron supplementation, and blood transfusions. The adjusted probabilities of prescribing ESAs were 31% (odds ratio (OR) = 0.69, 95% confidence interval (CI): 0.67-0.71) and 59% (OR = 0.41, 95% CI: 0.40, 0.42) lower in the post-TREAT and post-FDA warning periods compared to pre-TREAT period. The probability of prescribing intravenous iron was increased in the post-FDA warning period (OR = 1.11, 95% CI: 1.03-1.19) although the increase was not statistically significant in the post-TREAT period (OR = 1.03, 95% CI: 0.94-1.12). The probabilities of prescribing blood transfusion during the post-TREAT and post-FDA warning periods increased by 14% (OR = 1.14, 95% CI: 1.06-1.23) and 31% (OR = 1.31, 95% CI: 1.22-1.39), respectively. Similar trends of prescribing ESAs and iron supplementations were observed in commercially insured CKD patients but the use of blood transfusions did not increase.After the 2011 FDA safety warnings, the use of ESA continued to decrease while the use of iron supplementation continued to increase. The use of blood transfusions increased significantly in Medicare patients while it remained stable in commercially insured patients. Results suggest the TREAT publication had effected treatment of anemia prior to the FDA warning but the FDA warning solidified TREAT's recommendations for anemia treatment for non- dialysis dependent CKD patients." @default.
• W2899694001 created "2018-11-16" @default.
• W2899694001 creator A5048393571 @default.
• W2899694001 creator A5061638095 @default.
• W2899694001 creator A5071309777 @default.
• W2899694001 creator A5075594125 @default.
• W2899694001 creator A5077717253 @default.
• W2899694001 date "2018-11-09" @default.
• W2899694001 modified "2023-10-13" @default.
• W2899694001 title "Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006–2015)" @default.
• W2899694001 cites W1992965008 @default.
• W2899694001 cites W1995817487 @default.
• W2899694001 cites W1998943227 @default.
• W2899694001 cites W2022953798 @default.
• W2899694001 cites W2033803279 @default.
• W2899694001 cites W2040029744 @default.
• W2899694001 cites W2044108200 @default.
• W2899694001 cites W2072509148 @default.
• W2899694001 cites W2078846149 @default.
• W2899694001 cites W2096940954 @default.
• W2899694001 cites W2104810766 @default.
• W2899694001 cites W2110132657 @default.
• W2899694001 cites W2111094109 @default.
• W2899694001 cites W2134487085 @default.
• W2899694001 cites W2138687178 @default.
• W2899694001 cites W2154560753 @default.
• W2899694001 cites W2177121231 @default.
• W2899694001 cites W2416511603 @default.
• W2899694001 cites W2416547532 @default.
• W2899694001 cites W2580449060 @default.
• W2899694001 cites W2584947097 @default.
• W2899694001 cites W4210992511 @default.
• W2899694001 cites W4301717156 @default.
• W2899694001 doi "https://doi.org/10.1186/s12882-018-1119-7" @default.
• W2899694001 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6230235" @default.
• W2899694001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30413150" @default.
• W2899694001 hasPublicationYear "2018" @default.
• W2899694001 type Work @default.
• W2899694001 sameAs 2899694001 @default.
• W2899694001 citedByCount "23" @default.
• W2899694001 countsByYear W28996940012019 @default.
• W2899694001 countsByYear W28996940012020 @default.
• W2899694001 countsByYear W28996940012021 @default.
• W2899694001 countsByYear W28996940012022 @default.
• W2899694001 countsByYear W28996940012023 @default.
• W2899694001 crossrefType "journal-article" @default.
• W2899694001 hasAuthorship W2899694001A5048393571 @default.
• W2899694001 hasAuthorship W2899694001A5061638095 @default.
• W2899694001 hasAuthorship W2899694001A5071309777 @default.
• W2899694001 hasAuthorship W2899694001A5075594125 @default.
• W2899694001 hasAuthorship W2899694001A5077717253 @default.
• W2899694001 hasBestOaLocation W28996940011 @default.
• W2899694001 hasConcept C105795698 @default.
• W2899694001 hasConcept C126322002 @default.
• W2899694001 hasConcept C156957248 @default.
• W2899694001 hasConcept C167135981 @default.
• W2899694001 hasConcept C177713679 @default.
• W2899694001 hasConcept C194828623 @default.
• W2899694001 hasConcept C27403532 @default.
• W2899694001 hasConcept C2778248108 @default.
• W2899694001 hasConcept C2778653478 @default.
• W2899694001 hasConcept C2779978075 @default.
• W2899694001 hasConcept C33923547 @default.
• W2899694001 hasConcept C44249647 @default.
• W2899694001 hasConcept C53084192 @default.
• W2899694001 hasConcept C54847362 @default.
• W2899694001 hasConcept C71924100 @default.
• W2899694001 hasConceptScore W2899694001C105795698 @default.
• W2899694001 hasConceptScore W2899694001C126322002 @default.
• W2899694001 hasConceptScore W2899694001C156957248 @default.
• W2899694001 hasConceptScore W2899694001C167135981 @default.
• W2899694001 hasConceptScore W2899694001C177713679 @default.
• W2899694001 hasConceptScore W2899694001C194828623 @default.
• W2899694001 hasConceptScore W2899694001C27403532 @default.
• W2899694001 hasConceptScore W2899694001C2778248108 @default.
• W2899694001 hasConceptScore W2899694001C2778653478 @default.
• W2899694001 hasConceptScore W2899694001C2779978075 @default.
• W2899694001 hasConceptScore W2899694001C33923547 @default.
• W2899694001 hasConceptScore W2899694001C44249647 @default.
• W2899694001 hasConceptScore W2899694001C53084192 @default.
• W2899694001 hasConceptScore W2899694001C54847362 @default.
• W2899694001 hasConceptScore W2899694001C71924100 @default.
• W2899694001 hasIssue "1" @default.
• W2899694001 hasLocation W28996940011 @default.
• W2899694001 hasLocation W28996940012 @default.
• W2899694001 hasLocation W28996940013 @default.
• W2899694001 hasLocation W28996940014 @default.
• W2899694001 hasOpenAccess W2899694001 @default.
• W2899694001 hasPrimaryLocation W28996940011 @default.
• W2899694001 hasRelatedWork W1855024394 @default.
• W2899694001 hasRelatedWork W1988971925 @default.
• W2899694001 hasRelatedWork W2063585734 @default.
• W2899694001 hasRelatedWork W2070243348 @default.
• W2899694001 hasRelatedWork W2084081473 @default.
• W2899694001 hasRelatedWork W2169152159 @default.
• W2899694001 hasRelatedWork W2363926121 @default.
• W2899694001 hasRelatedWork W2583382473 @default.
• W2899694001 hasRelatedWork W2203203921 @default.
• W2899694001 hasRelatedWork W2810368072 @default.
• W2899694001 hasVolume "19" @default.

• next